Proteasome inhibition is a novel treatment for several hematological malignancies. However, resistance to the proteasome inhibitor bortezomib (BTZ, Velcade) is an emerging clinical impediment. Mutations in the b5 subunit of the proteasome, the primary target of BTZ, have been associated with drug resistance. However, the exact mechanism by which these mutations contribute to BTZ resistance, is still largely unknown. Toward this end, we here developed BTZ-resistant multiple myeloma (8226) and acute lymphoblastic leukemia (CCRF-CEM) cell line models by exposure to stepwise increasing concentrations of BTZ. Characterization of the various BTZresistant cells revealed upregulation of mutant b5 subunit of the proteasome. These newly identified b5-subunit mutations, along with previously described mutations, formed a mutation cluster region in the BTZ-binding pocket of the b5 subunit, that of the S1 specificity pocket in particular. Moreover, we provide the first evidence that the mechanism underlying BTZ resistance in these tumor cells is impaired binding of BTZ to the mutant b5 subunit of the proteasome. We propose that proteasome subunit overexpression is an essential compensatory mechanism for the impaired catalytic activity of these mutant proteasomes. Our findings further suggest that second-generation proteasome inhibitors that target the a7 subunit of the proteasome can overcome this drug resistance modality.
Introduction
The ubiquitin proteasome system controls multiple key cellular homeostasis processes including cell cycle, signal transduction, DNA repair, immune and inflammatory responses, growth and differentiation. 1 Proteins targeted for degradation are tagged with multiple ubiquitin residues by a variety of E1, E2 and E3 ligases and degraded by the 26S proteasome. This latter complex consists of a 19S lid complex and a 20S core complex. The 19S is responsible for recognizing and unfolding ubiquinated proteins, whereas the 20S complex carries out the subsequent cleavage of the unfolded protein. The barrel-shaped 20S complex consists of two a-and two b-subunit rings, each of which contains seven different a or b subunits. Upon immune stimulation by, for example, interferon-g, the constitutive catalytic subunits b1 (PSMB6), b2 (PSMB7) and b5 (PSMB5), are replaced by their immune cognate forms; b1i (PSMB9), b2i (PSMB10) and b5i (PSMB8). 2, 3 Recently it has been shown that these immune forms are highly efficient in protein degradation, thus preventing aggresome formation. 4 The boronic dipeptide bortezomib (BTZ, Velcade, Millennium Pharmaceuticals Inc., The Takeda Oncology Company, Cambridge, MA, USA) inhibits the ubiquitin proteasome system by reversibly inhibiting the chymotrypsin-like activity of the b5 subunit of the proteasome and to a lesser extent also the caspase-like activity of the b1 subunit. 5, 6 As a result of proteasome inhibition, BTZ induces cell death through various mechanisms including inhibition of nuclear factor-kB activity, 7 activation of p53, 8 accumulation of misfolded proteins, 9 c-Jun N-terminal kinase activation 10 and stabilization of cell cycle inhibitors. 11 BTZ has shown promising clinical responses in multiple hematological malignancies including acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), lymphoma and in particular multiple myeloma (MM), where BTZ is currently used as the first-line chemotherapeutic treatment (reviewed in Vink et al.
12
; Shah et al.
13
; Orlowski et al.
14 ) Despite the good initial clinical response, some of the MM patients eventually become refractory or relapse after BTZ treatment. 13, 15 In addition, BTZ resistance also seems to occur in ALL. 16 Different mechanisms of BTZ resistance have been suggested; Kraus et al. 17 hypothesized, based on a BTZ-resistant AML cell line model and ex vivo primary patient samples, that quantitative alterations in the ratio between b2 type and (b1 þ b5) type of active proteasomal polypeptides induce BTZ resistance. Rü ckruch et al. 18 showed upregulation of the proteasomal machinery in BTZ-resistant AML and MM model cell lines. In addition to upregulation, we as well as others have identified single point mutations in PSMB5, which encodes for the b5 subunit of the proteasome, the primary target of BTZ, in BTZ-resistant AML, ALL and MM cell lines. [19] [20] [21] Here we provide the first evidence that the mechanism underlying BTZ resistance in ALL and MM cells is impaired binding of BTZ to a mutant b5 subunit of the proteasome. This is further substantiated by the identification of multiple novel b5-subunit mutations in various BTZ-resistant cell lines, which form a mutation cluster region in the BTZ-binding pocket of the b5 subunit of the proteasome or its close vicinity. We propose that proteasome subunit overexpression is a compensatory mechanism for the impaired catalytic activity of such mutant proteasomes.
Materials and methods

Cell culture and development of BTZ-resistant cell lines
Human T-ALL CCRF-CEM cells and human MM RPMI-8226 cells (ATCC, Manassas, VA, USA) were cultured in RPMI-1640 medium containing glutamine (Invitrogen/Gibco (Carlsbad, CA, USA) supplemented with 10% fetal calf serum (Greiner Bio-One, Alphen a/d Rijn, The Netherlands) and 100 mg/ml penicillin/streptomycin (Invitrogen) at 5% CO 2 and 37 1C. Cell cultures were seeded at a density of 3 Â 10 5 cells/ml and refreshed twice weekly. BTZ-resistant CCRF-CEM and RPMI-8226 cells were obtained by stepwise increasing extracellular concentrations of BTZ over a period of 4-15 months, respectively.
Computational modeling of b5 mutations
For the mutation modeling analysis, the yeast proteasomal crystal structure in complex with BTZ (MMDB ID: 38209, PDB ID: 2F16), 22 the yeast proteasomal crystal structure in complex with epoxomicin (MMDB ID: 14501, PDB ID: 1G65 (ref. 23) and the bovine proteasomal crystal structure (MMDB ID: 19465, PDB ID: 1IRU) 24 were used as templates. BTZ was manually docked into the bovine b5 subunit using Molecular Operating Environment (MOE) v2009 (Chemical Computing Group, Montreal, Quebec, Canada) and energy minimized using the Assisted Model Building with Energy Refinement (Amber99) force field. 25 The b5 and b6 subunit together with crystal water molecules within a radius of 4.5 Å from any atom of the ligand were used for further analysis. Hydrogen atoms were added using the corresponding tool in MOE. The peptide backbone of epoxomicin was used as scaffold for the generation of the coordinates of the substrate N-Succinyl-Leu-Leu-Val-Tyr-7-amino-4-methylcoumarin (suc-LLVY-AMC). Missing side chains of this substrate were added using the builder tool of MOE and after addition of hydrogen atoms, its structure was energy minimized in complex with the b5 and b6 subunit of the yeast proteasome. Subsequently, the suc-LLVY-AMC was manually docked into the b5-subunit-binding pocket within the bovine crystal structure. Mutations were manually introduced in the, thus, obtained BTZ-bound and suc-LLVY-AMC-bound complexes, followed by an exploration of the possible orientations of the newly introduced amino-acid side chains (using the rotamerexplorer utility of MOE) and subsequent energy minimization. All energy minimizations were performed using the Amber99 force field as implemented in MOE.
Supplementary data
Information on antibodies and drugs, cell growth inhibition, immunoblotting (western blotting and native gels), reverse transcription-PCR and sequence analysis can be found in Supplementary Document S1 and Supplementary Table S1 .
Results
Generation of BTZ-resistant cell lines
To obtain BTZ-resistant model cell lines, human T-ALL CCRF-CEM and the MM 8226 cell lines were exposed to gradually increasing concentrations of BTZ starting at 0.2 nM of BTZ. Consequently, the BTZ-resistant sublines of CCRF-CEM and 8226 stably growing in the presence of 7 nM (CEM/BTZ7 and 8226/BTZ7), 100 nM (8226/BTZ100) and 200 nM BTZ (CEM/ BTZ200) were used for characterization of the underlying mechanism of BTZ resistance. Figure 1a summarizes the distinct time-course of acquisition of BTZ resistance in the various drugselected cell lines. CCRF-CEM cells rapidly acquired drug resistance to a concentration of 200 nM of BTZ within 4 months. Similarly, the previously published human AML THP-1 cell line required 6 months to achieve a drug resistance level of 200 nM BTZ. 20 In contrast, acquisition of BTZ resistance in the MM cell line 8226 was much slower as cells required 15 months to become resistant to 100 nM BTZ. Cytotoxicity assays revealed 10-fold and 170-fold BTZ resistance in CEM/BTZ7 and CEM/ BTZ200 cells, respectively, compared with parental CEM/wildtype (WT) cells (IC 50 :1.5±0.4 nM; Figure 1b) . 8226/BTZ7 and 8226/BTZ100 displayed fivefold and 43-fold BTZ resistance (IC 50 :2.6±0.3 nM; Figure 1c) . Together, these studies might imply that acute leukemia cells were more prone to become BTZ resistant than MM cells.
Cross-resistance profile of BTZ-resistant cells to proteasome inhibitors
We explored the sensitivity of BTZ-resistant cell lines to an assortment of proteasome inhibitors. respectively. This resistance level was lower than that observed for the parent drug BTZ (170-fold). CEM/BTZ7 and CEM/BTZ200 cells retained full sensitivity toward the proteasome inhibitor 5AHQ, which binds to the a7 subunit of the proteasome. 29 Similar results were observed in the MM BTZ-resistant 8226 sublines. 8226/BTZ100 cells showed a marked cross-resistance toward all tested proteasome inhibitors that target the b subunits, in particular to ONX 0914 (60-fold). Interestingly, 8226/BTZ7 cells largely retained parental cell sensitivity toward the second-generation proteasome inhibitor carfilzomib, the orally bioactive proteasome inhibitor ONX 0912, as well as the immunoproteasome inhibitor, ONX 0914. Consistent with BTZresistant CCRF-CEM cells, both 8226/BTZ7 and 8226/BTZ100 retained parental cell sensitivity to the a7 subunit-targeted proteasome inhibitor, 5AHQ. Hence, both CEM/BTZ200 and 8226/BTZ100 displayed cross-resistance to proteasome inhibitors. Differences in cross-resistance levels between CEM/BTZ200 and 8226/BTZ100 were most prominently found for MG132, carfilzomib and ONX 0912 (see Table 1 ). Together, these results demonstrate that cross-resistance of both ALL and MM BTZ-resistant cells is restricted to drugs that target the b subunits of the proteasome, whereas retaining sensitivity to proteasome inhibitors (5AHQ) that bind to b-subunit-independent components of the proteasome. Dissimilarities in crossresistance between the CEM/BTZ100 and 8226/BTZ100 to the various proteasome inhibitors may indicate distinct b-subunitrelated resistance mechanisms.
Upregulation of constitutive b subunits of the proteasome in BTZ-resistant cells BTZ displays a low nM inhibitory constant of the catalytic chymotrypsin-like activity of the eukaryotic proteasome. 22 Consistently, BTZ targets the b5 subunit of the proteasome at the low nM concentration range in these cell lines, whereas at higher concentrations, it also inhibits the b1 subunit. Because our cross-resistance data (Table 1 ) suggested a b-subunit-specific resistance mechanism, the expression pattern of the b1, b2 and b5 subunits of the proteasome was determined at the RNA and protein levels. Figure 2a depicts the mRNA expression levels of PSMB6 (b1), PSMB7 (b2) and PSMB5 (b5) as normalized to b-glucuronidase (GUS); only a minor elevation of all constitutive catalytic subunits was observed in both CEM/BTZ7 and CEM/ BTZ200 cells. A more profound upregulation of the mRNA for constitutive catalytic subunits was seen in BTZ-resistant MM 8226 cells. Moreover, 8226/BTZ100 cells showed a selective 15-fold upregulation of the PSMB5 gene. Subsequently, the expression profile of the proteasome catalytic subunits was determined at the protein level ( Figure 2b ). BTZ-resistant CEM cells displayed an upregulation of the constitutive catalytic b subunits, concurrent with elevated mRNA levels. In addition, an upregulation of the non-catalytic a7 subunit was also observed, indicating an upregulation of the whole 20S proteasome. In contrast to parental 8226 cells, BTZ100-resistant 8226 cells showed a more selective upregulation of the b5 subunit, whereas only a minor increment in the expression of the other subunits was observed. Intriguingly, this high mRNA level of the b5 subunit was not substantiated with higher proteins being comparable to the level of BTZ7. This may imply that additional post-transcriptional mechanisms contribute to the resistance. To confirm that the change in subunit expression also results in a parallel change in proteasome complex composition, native gel electrophoresis was performed as previously described by Elsasser et al. 30 Western blot analysis performed after native gel electrophoresis is shown in Figure 2c . Concurrent with the denaturing gel electrophoresis data (Figure 2b ), native gel electrophoresis also detected upregulation of both the b5 and a7 subunits in CEM/BTZ cells, indicating an upregulation of the entire 20S complex. Moreover, 8226/BTZ cells also showed a specific upregulation of the b5 subunit of the proteasome, which is incorporated in the 20S complex. The 20S proteasome consists of two a-and two b-rings. Because one b-ring consists of seven different b subunits, only one b5 subunit can be incorporated per b-ring. 24 Therefore, a shift in expression might occur from immunoproteasome toward constitutive proteasome expression. Figure 2e shows the relative expression of constitutive as well as the immunoproteasome b5 subunit (b5i) using an enzyme-linked immunosorbent assay approach as described previously. 31 In BTZ-resistant 8226 cells, a remarkable shift in expression of the b5i to constitutive b5 subunit was observed. In contrast, BTZ-resistant CEM cells showed no alteration in the ratio between immune and constitutive proteasome subunit; these results were confirmed using native gel electrophoresis (Figure 2d ). Hence, these findings reveal decreased incorporation of immune b5i subunit in the BTZ-resistant 8226 cells, which exhibited a near complete substitution of the immunoproteasome by the constitutive proteasome. Alternatively, drug-resistant CEM cells show a similar upregulation of both b5i and b5.
Identification of multiple mutations in the PSMB5 gene in 8226/BTZ and CEM/BTZ cells
We sequenced the PSMB5, PSMB6 and PSMB7 (encoding for the b5, b1 and b2 subunits, respectively) at the genomic DNA level. The low BTZ-resistant CEM/BTZ7 cells harbored a mutation in the PSMB5 gene; a single-nucleotide substitution (G332T) was identified, hence, resulting in a cysteine to phenylalanine substitution at amino-acid position 52 of the b5 subunit. Moreover, CEM/BTZ200 cells gained an additional mutation (C323T), resulting in an Ala49Val substitution in the b5 subunit. The latter mutation is a substitution at the same position previously published in THP1/BTZ100 cells, only resulting in a different amino-acid substitution (Ala49Thr). This amino acid has been described by Groll et al. 22 to be directly involved in BTZ binding. The position of the first mutation (Cys52Phe) has not been described as being involved in direct BTZ binding. However, it resides in a close proximity to Met45; it has been suggested that this latter amino acid undergoes a conformational change before BTZ binding to the b5 subunit. 22 Initially, the low-level drug-resistant 8226/BTZ7 cells had no detectable mutation in the PSMB5 gene. However, upon prolonged culturing of these BTZ-resistant cells in the presence of 7 nM BTZ for several weeks, a mutation (A247G) emerged that resulted in a Thr21Ala substitution in the b5 subunit. 8226/ BTZ100 cells lost this Thr21Ala mutation, but gained the Ala49Thr substitution that was originally identified in THP1/ BTZ100 cells. Both Thr21 and Ala49 reside in the BTZ-binding pocket of the b5 subunit of the proteasome and were previously identified as being directly involved in BTZ binding. 22 Sequencing of the PSMB6 and PSMB7 genes did not reveal any mutations in both parental CEM and 8226 cells, and BTZ-resistant counterparts. Likewise, no PSMB5 gene mutations were identified in parental cells grown in parallel with 8226 and CEM cells during the course of exposure to increasing BTZ concentrations (results not shown).
To distinguish between the expansion of a pre-existing b5 subunit mutant subclone and the de novo acquisition of a mutation and its subsequent outgrowth, we generated a second and independent panel of BTZ-resistant CEM and THP1 cells termed CEM/BTZ100N and THP1/BTZ100N, respectively. These new BTZ-resistant cell lines were established using precisely the same drug selection protocol used for the original BTZ-resistant cell lines. Interestingly, different mutations were found in the newly obtained cell lines; THP1/BTZ100N cells acquired an A310G mutation resulting in a Met45Val substitution in the b5 subunit. Remarkably, the THP1/BTZ500 cell line had the same Met45lle substitution. Furthermore, CEM/BTZ100N cells displayed the same G322A mutation as observed in 8226/ BTZ100 and THP1/100, but this mutation was not previously seen in CEM/BTZ200 cells. A summary of the multiple b5-subunit mutations is depicted in Table 2 . Hence, these data indicate that prolonged BTZ exposure results in de novo acquisition of multiple mutations in the PSMB5 gene, thereby resulting in amino-acid substitutions within the BTZ-binding pocket, that are presumably directly or indirectly involved in BTZ binding.
Mutations identified in this study as well as in previous studies formed a mutation cluster region at both the nucleotide and the protein levels (Figures 3a and b) . Although the Thr21Ala mutation seemed to be an outlier, when mutations are positioned within the three dimensional (3D) structure of the proteasome's b5 subunit, all mutations cluster around the BTZ-binding pocket (Figure 3c) . Moreover, the vast majority of the mutations reside around the S1 specificity pocket of the b5 subunit. This S1 specificity pocket is mainly responsible for recognizing the peptide bond of the substrate that is to be cleaved. 22, 32 The first side chain (P1) of proteasome's substrates as counted from the Thr1-binding residue, binds to the S1 specificity pocket. Part of the specificity of proteasome inhibitors is therefore mediated by the P1 side chain of the drug. 33 As a result, mutations in the S1 pocket can have crucial adverse consequences for proteasome inhibitor binding.
Acquired b5-subunit mutations induce amino-acid substitution in the BTZ-binding pocket that hinder BTZ binding
To investigate the influence of mutations on the BTZ-binding capacity, we performed an in silico 3D modeling analysis of the mutated b5 subunit. To this end, we computationally explored the effect of the mutations on BTZ binding, using the crystal structure of the yeast 20S proteasome in complex with BTZ, 22 and using the complex structure obtained by manually docking BTZ into the WT bovine proteasome crystal structure. 24 Subsequently, mutations were manually introduced as described in Materials and methods. Figure 4a shows the predicted position of BTZ binding to the WT bovine b5 subunit, as well as critical residues involved in this binding.
In CEM/BTZ7 cells we identified a Cys52Phe substitution; as described previously by Groll et al., 22 Cys52 is not known to be directly involved in BTZ binding. However, it resides in the Amino-acid positions were calculated using the NP_002788 sequence, at the start of the processed proteins (starting at Thr60 of the unprocessed protein). S1-binding pocket of b5 subunit. Our analysis shows that introduction of a Phe group at position 52 would lead to a slight repulsion of BTZ from the S1 pocket (Figure 4b ). Furthermore, CEM/BTZ200 acquired an additional Ala49Val substitution. The amino acid at this position has been found to be directly involved in BTZ binding 22 and has been described by Lu et al. 34 to be involved in conferring BTZ resistance. After introducing the Ala49Val mutation into the Cys52Phe mutant, we did not observe a direct steric clash of the additional methyl groups and BTZ atoms, although the distance between the methyl group and the BTZ P1 side chain, is only 3.3 Å . Moreover, Heinemeyer et al. 35 suggested that Ala49Val substitution restricts accessibility to the S1 pocket. Therefore, introducing residues with a larger side chain might negatively affect BTZ binding, by hampering the accessibility of P1 to the S1 pocket. This is illustrated by our structural analysis of ligand binding to the Ala49Thr mutant (see below).
8226/BTZ7cells harbored a previously undescribed Thr21Ala mutation. This mutation was initially heterozygous, but after prolonged exposure to 7 nM BTZ, it became homozygous. Thr21 has been described by Groll et al. 22 to be directly involved in BTZ binding. Substitution of this residue will result in a loss of a protein-ligand hydrogen bond (compare Figures 4a and c) , which is likely to decrease BTZ affinity to the b5 subunit. The 8226/BTZ7 cell line was still heterozygous when BTZ concentrations were increased toward 100 nM, whereas upon the establishment of 8226/BTZ100 cells, the Thr21Ala substitution was lost and replaced by the Ala49Thr substitution. This latter mutation has been described previously in the BTZresistant Jurkat (T-ALL), 19 THP-1 (AML) cell lines 20 and recently also in a BTZ-resistant 8226MM cell line. 21 This amino acid has been also described to be directly involved in BTZ binding via a hydrogen bond network between Ala49, Ala50, Asp114 of the b6 subunit and a well-defined H 2 O molecule. Depending on the orientation of its side chain, either steric interference with the BTZ backbone (Figure 4d) or closure of the S1 pocket (Figure 4e ) was observed upon introducing Thr49. Both effects are expected to have a negative influence on BTZ binding to the b5 subunit.
Mutations on the Met45 position did not reveal a direct effect on BTZ binding in our in silico analysis. However, this amino acid has been described previously to be crucial in determining S1 pocket specificity. 22, 31 Moreover, this amino acid has to undergo a conformational change upon BTZ binding, thereby resulting in an induced fit. 22 Substitutions at this Met45 can therefore have a marked impact on the dynamics of BTZ binding by altering the binding pocket's specificity and flexibility. Together, the in silico data suggest that all acquired mutations decrease the affinity of the b5-binding pocket to BTZ, and particularly of the S1-binding pocket.
Mutations in b5 subunit hinder suc-LLVY-AMC binding
Because the S1 pocket of the b5 subunit is crucial for substrate recognition, we hypothesized that acquired mutations in BTZ-resistant cells are likely to affect substrate binding that is widely used in studies on proteasome's catalytic activity. We performed in silico 3D modeling analysis of the b5-substrate tetrapeptide suc-LLVY-AMC. For our in silico 3D structural studies, we used a crystal structure of the yeast proteasome in complex with epoxomicin 23 and we used epoxomicin as a scaffold to generate atomic coordinates for bound suc-LLVY-AMC substrate. In addition, the substrate was docked into the WT bovine crystal structure of the proteasome, after which we introduced the different b5-subunit mutations. Figure 5a shows the prediction of the binding pose of the suc-LLVY-AMC substrate in the WT bovine b5 subunit. The P1 Tyr residue of the substrate binds to the S1 specificity pocket of the b5 subunit. Introducing the Cys52Phe mutation into the complex shows that the P1 Tyr group of the substrate is displaced by Phe52 (Figure 5b ), which will negatively affect binding affinity. Moreover, the conformational change of Met45 necessary for substrate binding (as discussed above), might also be hindered. The additional introduction of Ala49Val was found to repel the P1 chain further out of the S1 pocket (Figure 5c ). This is in line with data of Heinemeyer et al. 35 who showed decreased conversion of Cbz-Gly-Gly-Leu-4-nitroanalide in Ala49Val mutated b5 subunit in the yeast proteasome. In our in silico studies, the side chain of Thr21 does not seem to be directly involved in binding of the suc-LLVY-AMC substrate, although this Thr residue is in close proximity to the peptide backbone of the substrate (Figure 5a ). Minor Figure 3 Mutations in the b5 subunit form a cluster region. Mutations described in this study cluster together with previously published papers in DNA (a) and protein sequence (b). Represented mutations are described in: current paper, Oerlemans et al., 20 Lu et al., 34 Lu et al. 19 and Ri et al.
21
(c) Graphic representation of the 3D protein-backbone structure of the b5 subunit. Mutations are depicted in green. P1, substrate side chain 1; S1, specificity binding pocket 1.
conformational changes may therefore result in a hydrogen bond between the Thr21 side chain and the backbone of LLVY. Therefore, the replacement of Thr by Ala may also hamper substrate binding (data not shown). Introduction of the Ala49Thr mutation leads again to changes in the S1 pocket. As in case of BTZ, Thr49 can hamper P1 access for suc-LLVY-AMC to the specificity pocket (Figure 5d) . Addition of the Met45Ile mutation further pushes the P1 group further out of the S1 pocket (Figure 5e ). In conclusion, the 3D structural analysis of suc-LLVY-AMC binding to b5 subunit suggests that the experimentally observed mutations negatively affect the substrate's affinity to the binding pocket.
Residual b5 proteasomal activity in BTZ-resistant cells
The in silico 3D modeling analysis of BTZ and suc-LLVY-AMC in complex with the mutated b5 subunit suggests that the observed mutations compromise BTZ as well as suc-LLVY-AMC binding. To investigate the binding capacity of the BTZ pocket in vitro, native gel electrophoresis was performed with equal amounts of protein extracts, followed by in-gel b5-activity assay using the suc-LLVY-AMC substrate, as described previously. 20, 30 Figure 6a shows the effect of BTZ on in-gel activity harbored by the core particle of the proteasome in parental CEM and 8226 cells and their BTZ-resistant sublines. For parental CEM and 8226 cells, a steep dose-response effect is noted with a marked inhibition of in-gel proteasome activity at 7 nM BTZ and complete inhibition at 25 nM BTZ. For low-level (BTZ7) and high-level (BTZ100/200) BTZ-resistant cells, exposure to BTZ confers a less efficient inhibition upon in-gel proteasome activity assay than in parental cells. Because a significant loss of function of proteasome activity would lead to accumulation of ubiquitinated proteins, 36 total protein ubiquitination levels were investigated in the BTZ-resistant cells. Figure 6b compares the sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE)-resolved ubiquitinated proteins of untreated cells with 24 h of treatment with BTZ. For parental cells, both low-dose BTZ concentrations (that is, 7 nM; 3-4-fold IC 50 ) and higher BTZ concentrations (25 nM) were used. For each cell line, experiments were performed either in the absence of drug (parental cells), at their selective BTZ concentrations (7 nM for 8226/BTZ7 and CEM/ BTZ7, 100 nM for 8226/BTZ100 and 200 nM for CEM/BTZ200), as well as BTZ concentrations of at least 2.5-fold beyond selective concentrations. Both parental CEM/WT and 8226/WT cells showed a dose-dependent increase of polyubiquinated proteins upon exposure to BTZ. In contrast, BTZ-resistant cells did not show an accumulation of polyubiquinated proteins at their selective drug concentrations of 100 and 200 nM BTZ, respectively. However, at very high concentrations (that is, 500 nM), BTZ was able to induce the accumulation of ubiquinated proteins, indicating that the ubiquitination machinery in BTZ-resistant cells was still capable of responding by accumulation of ubiquitinated proteins when mutated b5-subunit-associated proteasome activity is fully blocked at high BTZ concentrations. 
Discussion
This study provides several lines of evidence for the involvement of multiple mutations in the b5 subunit of the proteasome in BTZ resistance in different hematological malignancy cell line models: (1) multiple mutations in the BTZ-binding pocket of the b5 subunit were identified, which mapped to a mutation cluster region in the established catalytic site, (2) we obtained 3D modeling evidence to support decreased BTZ affinity to the mutant b5 subunits, (3) the b5 proteasomal subunit was substantially overexpressed in BTZ-resistant cells, (4) a near complete substitution of the immune form of the b5 subunit by the constitutive mutated form, occurred in BTZ-resistant 8226 cells, (5) BTZ-resistant cells displayed a marked cross-resistance to proteasome inhibitors, which selectively target b subunits, but not the a7 subunit and (6) finally, BTZ-resistant cells showed sustained overall proteasomal activity indicated by decreased accumulation of ubiquitinated proteins after exposure to BTZ.
Mutations in cellular enzymes targeted by chemotherapeutic drugs is a well-established modality of drug resistance. [37] [38] [39] This is also the case with BTZ resistance; we and others have reported mutations in the b5 subunit in pre-clinical BTZ-resistant cell line models. 20, 21, 34, 40 In this study, we identified four novel mutations, all residing within the BTZbinding pocket, and cluster with the previously reported G322A (Ala49Thr) 20, 21, 40 and C323T (Ala49Val) 34 mutations. The BTZ-binding pocket, particularly the S1 pocket, proved to be a 'hot spot' for mutations associated with BTZ resistance. In silico analysis of these amino-acid substitutions revealed that Ala49Thr, Ala49Val and Thr21Ala are directly involved in BTZ binding, and therefore, presumably result in decreased BTZbinding affinity via loss of hydrogen bonds between BTZ and the b5 subunit, and by hampering accessibility to the S1 specificity pocket. The Cys52Phe mutation was found to cause repulsion of BTZ's P1 side chain out of the S1 pocket. The Met45Ile and Met45Val substitutions were not found to directly interact with BTZ. However, Met45 resides in the S1 specificity pocket and contributes to its specificity. Moreover, upon binding, Met45 is known to undergo a conformational change and shifts the direction of its side chain toward Cys52 vicinity. 22 Alterations in Met45 might therefore compromise BTZ binding as well. It is not clear how the Thr21Ala is lost and replaced by a Ala49Thr in the 8226 cells upon additional selective pressure. It has been established in drug-resistant cancer cells that the mutated gene can revert to WT by an additional mutation event. 41, 42 Loss of a mutation can in general also be explained by loss of heterozygosity (losing the mutated gene) or oligoclonality (disappearance of one subclone and emergence of another subclone with a different mutation). Which one of the processes have occurred in this BTZ-resistant cell line remains to be elucidated. Together, our in silico modeling data suggest that all identified mutations can decrease the affinity of the b5-binding pocket to BTZ.
Because the S1 pocket is also involved in substrate binding, we determined the influence of the mutations in the b5 subunit on suc-LLVY-AMC substrate binding. Using the crystal structure of the proteasome in complex with epoxomicin, which has structural similarity to the backbone of the suc-LLVY-AMC substrate, 23, 34 in silico structural prediction of the b5 subunit in complex with suc-LLVY-AMC was performed, suggesting decreased binding affinity of this substrate in the mutant b5 in BTZ-resistant cells. These in silico results were confirmed using b5-activity assay after native gel electrophoresis, which showed a profound decreased conversion of suc-LLVY-AMC in 8226/ BTZ100 protein extract, although the b5 subunit was heavily overexpressed. Similar results were obtained with protein extracts from CEM/BTZ200 cells, albeit to a lesser extent. These cumulative findings suggest that cells harboring a mutant b5 subunit have impaired proteasome activity, relative to parental cells. Therefore, BTZ-resistant cells must compensate for this impaired activity via upregulation of the b5 subunit. Consistent with this notion is the observation that in cells harboring homozygous b5-subunit mutations, upregulation of the b5 subunit was even more pronounced when compared with cells harboring heterozygous mutations. These findings underline the tight relationship between impaired proteasome activity and subunit overexpression. This compensation of impaired catalytic activity by subunit upregulation was clearly shown in both 8226/100 and CEM/BTZ200 cells, although the mechanism is different. It is noteworthy that CEM/BTZ cells upregulate both the constitutive and immune forms of the proteasome. Therefore, it is likely that the WT b5 and b5i are responsible for the residual proteasome activity as determined in our native gel activity analysis with protein extracts from CEM/BTZ200 cells. In contrast, 8226/BTZ100 cells show a near complete substitution of the b5i subunit by the homozygous mutant constitutive b5 subunit, thereby resulting in almost no detectable in-gel activity. The residual activity detected is most likely mediated by the low residual expression of b5i subunit. Because the complete loss of proteasome function is not compatible with life, we wondered whether or not the overall proteolytic activity of the proteasome remains intact. In BTZresistant cells, upon exposure to selective BTZ concentrations, inhibition of proteasome activity is incomplete, hence sustained residual activity may still facilitate protein degradation without accumulation of ubiquitinated proteins. Only upon exposure to BTZ concentrations that are 2.5-5-fold higher than the selective concentrations of BTZ, proteasome activity is compromised, hence leading to accumulation of ubiquitinated proteins similar as observed for parental cells of low-dose BTZ. These results indicate that the ubiquitination machinery remained intact in the BTZ-resistant cells.
Interestingly, BTZ-resistant 8226 cells revealed a near complete shift of the b5i subunit to the constitutive b5 subunit. A similar shift in b5 and b5i expression profiles was previously reported by our laboratory for BTZ-resistant THP-1 AML cells. 20 These observations could be consistent with the notion that upregulation of a mutant constitutive b5 subunit in conjunction with a downregulation of a non-mutated, and thus BTZ-inhibitable b5i subunit, would set the stage for conferring the highest level of BTZ resistance.
BTZ-resistant cells show a marked cross-resistance toward proteasome inhibitors, which target the b5 subunit (Table 1) . Because BTZ-resistant cells retain full sensitivity to the a7 proteasome inhibitor 5AHQ, 29 their propensity to die from proteasome inhibition with inhibitors that target other proteasomal subunits remains fully intact. This latter finding bears an important implication for the successful treatment of such BTZ-resistant tumors with agents such as 5AHQ that do not target the structurally altered b5 subunit. On the basis of these findings, we propose a model in which acquired mutations in the b5 subunit attenuate BTZ binding and inevitably substrate binding, although the BTZ binding appears to be affected to a greater extent than natural substrates. Therefore, BTZ-resistant cells must rely on the upregulation of mutant b5 subunit to overcome this decreased proteasome activity, and thereby retain the crucial overall protein turnover function. This model is in accord with our previously published THP1/BTZ100 cells showing upregulation of the mutant b5 subunit without increment in b5 proteasomal activity. In addition, no accumulation of ubiquitinated proteins was observed after exposing the THP/BTZ100 to BTZ. 20 Consistently, Ri et al. 21 also found in their BTZ-resistant myeloma cell lines an Ala49Thr substitution and reduced accumulation of ubiquitinated proteins after 24 h. In contrast to our data, they showed increased proteasome activity in their BTZ-resistant lines harboring the Ala49Thr substitution. 21 Likewise, Lu et al. 34 showed increased proteasome activity of the b5-mutated proteasome. This difference might be explained by the specific chymotrypsin-like activity assay used; we used an in-gel activity assay vs a whole cell lysate 34 or intact cell 21 assay. Moreover, 8226/BTZ100 cells expresses the mutant b5 subunit with only a minor b5i expression, which indicates that the mutated b5 subunit is solely responsible for the observed chymotrypsin-like activity in 8226/BTZ100 cells.
Given the heterogeneity of the patterns of clinical resistance to BTZ in MM, the molecular background of BTZ resistance may have a multifactorial basis. In the relapsed/refractory setting, the findings of the APEX study support the existence of inherent drug resistance as reflected by the 50% of patients that either lacked any response or displayed a progressive disease. 43 However, there is also convincing evidence for acquired BTZ resistance from clinical practice. Specifically, BTZ treatment of patients experienced progressive disease during BTZ treatment and BTZ based re-treatment as second-line therapy is known to be less efficient compared with BTZ treatment of patients who were BTZ-naïve. 44, 45 These observations may support the hypothesis of the emergence of BTZ-resistant clones upon proteasome inhibitor-based drug therapy, and hence, supported clonal selection following cycles of retreatment. Such post-drug treatment specimens were not available for analysis in this study, because progressive disease is generally defined by an increase in M protein levels in combination with CRAB criteria (elevated Calcium, Renal failure, Anemia and Bone lesions), without the need for bone marrow analysis. Notwithstanding this fact, we screened for PSMB5 mutations in 14 bone marrow samples of MM patients at diagnosis before treatment with BTZ. Although two patients were found to be clinically refractory to treatment, no PSMB5 mutations were identified (results not shown). Moreover, other research groups also sequenced the PSMB5 gene in small groups of MM patients before BTZ treatment and did not detect mutations. 21, 46 Because data from this study suggest that PSMB5 mutations are induced and/or selected during exposure to BTZ, collection of samples during treatment is warranted as part of a prospective study design. This is underscored by the recent publication of Shaughnessy et al. 47 who provide evidence for a 48-h post-BTZ gene expression profile of 80 genes, which significantly overlaps with proteasome pathway-related genes including PSMD4. Moreover, this profile was correlated with shorter progression-free survival and overall survival.
It was of interest to note that PSMB5 mutations emerged more rapidly during in vitro BTZ exposure in leukemia cells of T-cell origin (CCRF-CEM cells) than in 8226 MM cells. It remains to be determined whether or not this is representative of the clinical setting. In fact, this will be investigated as part of an ongoing study that our laboratory is coordinating for childhood relapsed ALL treated with BTZ-containing chemotherapy. For this purpose we have set up and validated a sensitive high-resolution melting analysis method for detecting each of the PSMB5 mutations identified in this study.
In conclusion, our data show that prolonged in vitro exposure of cells of hematologic malignancies to BTZ, leads to mutations in the PMSB5 gene that result in amino-acid substitutions residing in, or in close proximity to the BTZ-binding pocket in the b5 subunit. We provide evidence that support the model that alterations in the BTZ pocket result in decreased BTZ binding, hence, forcing the mutant cells to compensate for this impaired catalytic activity by upregulation of the b5 subunit. These results may have important clinical implications; we show that second-generation proteasome inhibitors directed against a7 subunits can overcome this BTZ resistance in cells harboring b5-subunit mutations, hence offering a potential future treatment modality.
